All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Modified multivalent poly-N-acetyllactosamine glycans as novel ligands of human galectin-3

Public support

  • Provider

    Czech Science Foundation

  • Programme

    International projects

  • Call for proposals

    Mezinárodní projekty 10 (SGA0201500003)

  • Main participants

    Mikrobiologický ústav AV ČR, v. v. i.

  • Contest type

    VS - Public tender

  • Contract ID

    15-02578J

Alternative language

  • Project name in Czech

    Modifikované multivalentní poly-N-acetyllaktosaminové glykany jako nové ligandy pro lidský galektin-3

  • Annotation in Czech

    Sacharidy jsou nyní považovány za důležité nosiče informací v buněčných procesech. Pro fyziologickou aplikaci sacharidů je třeba aplikovat koncept multivalence, což je dáno slabými interakcemi sacharid-protein. Projekt se bude zabývat syntézou nových modifikovaných poly-laktosamininových glykanů a jejich výzkumem jako multivalentních ligandů lidského lektinu Gal-3. Vyvineme syntetickou strategii pro generování knihovny rozvětvených a modifikovaných multivalentních poly-laktosaminidových glykanů. Další modifikace terminálního typu 2 LacNAc jednotek (Galβ4GlcNAc) typem 1 LacNAc (Galβ3GlcNAc), LacDiNAc (GalNAcβ4GlcNAc) epitopů a dále biotinové skupiny vazané na Gal-jednotky budou zavedeny do multivalntních poly-LacNAc struktur s cílem zvýšit jejich selektivitu k lektinu Gal-3. Všechny nově syntetizované glykanové struktury budou testovány na jejich inhibiční účinek vazby Gal-3 lektinu na asialofetuin (ASF) s využitím “Enzyme-Linked-Lectin-Assay” (ELLA). Technika povrchové plasmonové resonance (SPR) bude využita pro stanovení vazebných konstant multivalentních glykanů k lektinu Gal-3.

Scientific branches

  • R&D category

    ZV - Basic research

  • CEP classification - main branch

    CE - Biochemistry

  • CEP - secondary branch

    EI - Biotechnology and bionics

  • CEP - another secondary branch

    CC - Organic chemistry

  • OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)

    10401 - Organic chemistry<br>10608 - Biochemistry and molecular biology<br>10609 - Biochemical research methods<br>20801 - Environmental biotechnology<br>20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management<br>20803 - Environmental biotechnology related ethics<br>20901 - Industrial biotechnology<br>20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation<br>20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials<br>30401 - Health-related biotechnology<br>30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)<br>30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])<br>30404 - Biomaterials (as related to medical implants, devices, sensors)<br>30405 - Medical biotechnology related ethics<br>40401 - Agricultural biotechnology and food biotechnology<br>40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming<br>40403 - Agricultural biotechnology related ethics

Completed project evaluation

  • Provider evaluation

    U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)

  • Project results evaluation

    Modified poly-LAcNAc glycans were prepared by chemo-enzymatic synthesis, and tested on galectin-3. These multivalent glycoconjugates appear to be prospective for the diagnosis and therapy of some cardiovascular diseases in which galectin-3 expression is increased. The results were published in eight quality publications presented in journals with high impact factors.

Solution timeline

  • Realization period - beginning

    Jan 1, 2015

  • Realization period - end

    Dec 31, 2017

  • Project status

    U - Finished project

  • Latest support payment

    Apr 5, 2017

Data delivery to CEP

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

  • Data delivery code

    CEP18-GA0-GC-U/01:1

  • Data delivery date

    May 3, 2018

Finance

  • Total approved costs

    4,738 thou. CZK

  • Public financial support

    4,738 thou. CZK

  • Other public sources

    0 thou. CZK

  • Non public and foreign sources

    0 thou. CZK